A clinical perspective of the best combination therapy and MRD guided treatment for patients with CLL
In this MEDtalk, Professor Dr. Arnon P. Kater, CLL specialist at the Amsterdam Medical Centers, University of Amsterdam, gives his answer to the following two questions from Carsten Niemann, Associated Professor, MD, Ph.D., Department of Hematology, Rigshospitalet:
1. Do you think ibrutinib + venetoclax is better than rituximab + venetoclax for this group of patients?
2. Is the MRD-guided treatment in VISION/HO141 ready to be implemented in the daily clinic?